175 related articles for article (PubMed ID: 15507217)
1. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
Truong JG; Newman AH; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
[TBL] [Abstract][Full Text] [Related]
2. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Truong JG; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
[TBL] [Abstract][Full Text] [Related]
4. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
Wu J; Dougherty JJ; Nichols RA
J Neurochem; 2006 Jul; 98(2):481-94. PubMed ID: 16805841
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
Truong JG; Rau KS; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
[TBL] [Abstract][Full Text] [Related]
11. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
12. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
Eyerman DJ; Yamamoto BK
J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
14. Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.
Pickel VM; Chan J; Nirenberg MJ
Synapse; 2002 Aug; 45(2):113-24. PubMed ID: 12112404
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
17. PCB-induced inhibition of the vesicular monoamine transporter predicts reductions in synaptosomal dopamine content.
Bemis JC; Seegal RF
Toxicol Sci; 2004 Aug; 80(2):288-95. PubMed ID: 15115888
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
Ugarte YV; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Jul; 472(3):165-71. PubMed ID: 12871750
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
20. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats.
Yoshida ST; Baella SA; Stuebner NM; Crawford CA; McDougall SA
Brain Res; 2006 Feb; 1073-1074():269-75. PubMed ID: 16427034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
